It is known that Vitamin E, traditionally known as α¬ tocopherol, is a mixture of eight different compounds, four tocopherols and four tocotrienols, each one being designated as α, β, γ and δ forms. The two groups differ in the hydrophobic tridecyl side chain which is saturated (phytyl) in tocopherols and unsaturated having three double bonds (geranyl) in tocotrienols. During the last few years, it has been found that all the eight forms are biologically active and perform specific functions. Clinical research has shown that mixture of tocotrienols and tocopherols offer synergistic protective action against heart ailments and cancer that is not exclusively offered by α¬tocopherol. The other advantage of mixed tocopherols and tocotrienols is their role in slowing down aging. Diseases like diabetes 1 and 2, autoimmune diseases, bacterial and viral infections, Alzheimer disease, fungal (Candida) infections are prevented by these compounds. It helps in the maintenance of bones, muscles, eyes (vision), memory, sleep, lungs, infertility, skin and wrinkles. Although all forms of Vitamin E exhibit antioxidant activity, it is known that the antioxidant activity of vitamin E is not sufficient to explain the vitamin's biological activity. Vitamin E's anti-atherogenic activity involves the inhibition of the oxidation of LDL and the accumulation of oxLDL in the arterial wall. Vitamin E's antithrombotic and anticoagulant activities involves the downregulation of the expression of intracellular cell adhesion molecule(ICAM)-1 and vascular cell adhesion molecule(VCAM)-1 that lowers the adhesion of blood components to the endothelium. Its antioxidant effects explain the neuroprotective effects of vitamin E. The immunomodulatory effects of Vitamin E have been demonstrated in vitro, where alpha-tocopherol increases mitogenic response of T lymphocytes from aged mice. The mechanism of this response by vitamin E is not well understood, however it has been suggested that vitamin E itself may have mitogenic activity independent of its antioxidant activity. The mechanism of action of vitamin E's antiviral effects (primarily against HIV-1) involves its antioxidant activity. Vitamin E reduces oxidative stress, which is thought to contribute to HIV-1 pathogenesis, as well as to the pathogenesis of other viral infections. Vitamin E also affects membrane integrity and fluidity and, since HIV-1 is a membraned virus, altering membrane fluidity of HIV-1 may interfere with its ability to bind to cell-receptor sites, thus decreasing its infectivity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: O94759 Gene ID: 7226.0 Gene Symbol: TRPM2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23943124 |
|||
Target ID: P14174 Gene ID: 4282.0 Gene Symbol: MIF Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22281490 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Inactive ingredient | REVERSE IT KIT Approved UseSUNSCREEN Launch Date2014 |
|||
| Palliative | M.V.I. PEDIATRIC Approved UseThis formulation is indicated as daily multivitamin maintenance dosage for infants and children up to 11 years of age receiving parenteral nutrition. It is also indicated in other situations where administration by the intravenous route is required. Such situations include surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states, which may provoke a “stress” situation with profound alterations in the body’s metabolic demands and consequent tissue depletion of nutrients. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. M.V.I. Pediatric (reconstituted and administered in intravenous fluids under proper dilution) contributes intake of these necessary vitamins toward maintaining the body’s normal resistance and repair processes. Patients with multiple vitamin deficiencies or with markedly increased requirements may be given multiples of the daily dosage for two or more days as indicated by the clinical status. Blood vitamin concentrations should be monitored to ensure maintenance of adequate levels, particularly in patients receiving parenteral multivitamins as their sole source of vitamins for long periods of time. Launch Date2000 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The use of hydrogen peroxide to enhance the efficacy of doxorubicin hydrochloride in a murine bladder tumor cell line. | 2001-04 |
|
| The impact of phospholipid transfer protein (PLTP) on HDL metabolism. | 2001-04 |
|
| Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters. | 2001-04 |
|
| t-Butyl hydroperoxide and oxidized low density lipoprotein enhance phospholipid hydrolysis in lipopolysaccharide-stimulated retinal pericytes. | 2001-03-30 |
|
| Antioxidants prevent ethanol-induced contractions of canine cerebral vascular smooth muscle: relation to alcohol-induced brain injury. | 2001-03-30 |
|
| No reduction of alpha-tocopherol quinone by glutathione in rat liver microsomes. | 2001-03-15 |
|
| Growth reduction in glioma cells after treatment with tetradecylthioacetic acid: changes in fatty acid metabolism and oxidative status. | 2001-03-15 |
|
| Plasma concentrations of carotenoids, retinol, and tocopherols in preeclamptic and normotensive pregnant women. | 2001-03-15 |
|
| Effects of vitamin E on lipid peroxidation in healthy persons. | 2001-03-07 |
|
| Polychlorinated biphenyl-induced effects on metabolic enzymes, AP-1 binding, vitamin E, and oxidative stress in the rat liver. | 2001-03-01 |
|
| DNA strand breakage and oxygen tension: effects of beta-carotene, alpha-tocopherol and ascorbic acid. | 2001-03 |
|
| Diazepam submicron emulsions containing soya-bean oil and intended for oral or rectal delivery. | 2001-03 |
|
| Protection against nitrofurantoin-induced oxidative stress by coelenterazine analogues and their oxidation products in rat hepatocytes. | 2001-03 |
|
| Antioxidant status affects color stability and tenderness of calcium chloride-injected beef. | 2001-03 |
|
| Multivariate patterns of biochemical responses of Pinus ponderosa trees at field plots in the San Bernardino Mountains, southern California. | 2001-03 |
|
| Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-(alpha)-lipoic acid. | 2001-03 |
|
| Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate. | 2001-03 |
|
| Antioxidant activity of resveratrol compared with common food additives. | 2001-03 |
|
| Preparation and value assignment of Standard Reference Material 968c Fat-Soluble Vitamins, Carotenoids, and Cholesterol in Human Serum. | 2001-03 |
|
| Impaired arachidonic (20:4n-6) and docosahexaenoic (22:6n-3) acid synthesis by phenylalanine metabolites as etiological factors in the neuropathology of phenylketonuria. | 2001-03 |
|
| Fiberoptic and conventional phototherapy effects on the skin of premature infants. | 2001-03 |
|
| Enhanced level of n-3 fatty acid in membrane phospholipids induces lipid peroxidation in rats fed dietary docosahexaenoic acid oil. | 2001-03 |
|
| The growth inhibitory effect of conjugated linoleic acid on a human hepatoma cell line, HepG2, is induced by a change in fatty acid metabolism, but not the facilitation of lipid peroxidation in the cells. | 2001-02-26 |
|
| Interfacial properties of phosphatidylcholine bilayers containing vitamin E derivatives. | 2001-02 |
|
| Antioxidant and prooxidant roles for beta-carotene, alpha-tocopherol and ascorbic acid in human lung cells. | 2001-02 |
|
| Dietary patterns, nutrient intake and gastric cancer in a high-risk area of Italy. | 2001-02 |
|
| Vitamin E administration and reversal of neurological deficits in protein-energy malnutrition. | 2001-02 |
|
| Serum concentrations of carotenoids and vitamins A, E, and C in control subjects from five European countries. | 2001-02 |
|
| Acute effect of dietary stanyl ester dose on post-absorptive alpha-tocopherol, beta-carotene, retinol and retinyl palmitate concentrations. | 2001-02 |
|
| Normobaric hyperoxic stress in budgerigars: non-enzymic antioxidants. | 2001-02 |
|
| A comparison of the kinetics of low-density lipoprotein oxidation induced by copper or by gamma-rays: influence of radiation dose-rate and copper concentration. | 2001-02 |
|
| Ascorbic acid status and subsequent diastolic and systolic blood pressure. | 2001-02 |
|
| Hereditary vitamin-E deficiency. | 2001-02 |
|
| Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma. | 2001-02 |
|
| Soluble adhesion molecules, endothelial function and vitamin E in type 1 diabetes. | 2001-02 |
|
| Hyperlipidemia and reproductive failure in captive-reared alligators: vitamin E, vitamin A, plasma lipids, fatty acids, and steroid hormones. | 2001-02 |
|
| [Differences in plasma antioxidants according to socioeconomic level in Chilean women]. | 2001-01 |
|
| Regulation of heme oxygenase activity in rat liver during oxidative stress induced by cobalt chloride and mercury chloride. | 2001-01 |
|
| Oxidative insult in sheep red blood cells induced by T-butyl hydroperoxide: the roles of glutathione and glutathione peroxidase. | 2001-01 |
|
| Longitudinal vitamin and homocysteine levels in normal pregnancy. | 2001-01 |
|
| Eicosanoid production, thrombogenic ratio, and serum and LDL peroxides in normo- and hypercholesterolaemic post-menopausal women consuming two oleic acid-rich diets with different content of minor components. | 2001-01 |
|
| Removal of fat from cow's milk decreases the vitamin E contents of the resulting dairy products. | 2001-01 |
|
| Cacao liquor polyphenols reduce oxidative stress without maintaining alpha-tocopherol levels in rats fed a vitamin E-deficient diet. | 2001-01 |
|
| Scavenger receptor class B, type I is expressed in porcine brain capillary endothelial cells and contributes to selective uptake of HDL-associated vitamin E. | 2001-01 |
|
| Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. | 2001-01 |
|
| Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. | 2001-01 |
|
| Intravenous infusion of iron and tetrahydrofolate does not influence intrauterine uteroferrin and secreted folate-binding protein content in swine. | 2001-01 |
|
| [Use of antioxidants and trimetazidine in preparation of patients with ischemic heart disease for coronary angiography]. | 2001 |
|
| The antioxidant network of the stratum corneum. | 2001 |
|
| Bioconversion of vitamin E acetate in human skin. | 2001 |
Patents
Sample Use Guides
For vitamin E deficiency: a typical dose in adults is RRR-alpha tocopherol (natural vitamin E) 60-75 IU per day.
For the movement disorder called tardive dyskinesia: RRR-alpha-tocopherol (natural vitamin E) 1600 IU daily.
For improving male fertility: vitamin E 200-600 IU daily.
For Alzheimer's disease: up to 2000 IU daily. Combination therapy of donepezil (Aricept) 5 mg and vitamin E 1000 IU per day has been used for slowing memory decline in people with Alzheimer's disease.
For liver disease called non-alcoholic steatohepatitis: 800 IU daily in adults has been used; 400-1200 IU daily has been used in children.
For early Huntington's chorea: RRR-alpha-tocopherol (natural vitamin E) 3000 IU.
For rheumatoid arthritis pain: vitamin E 600 IU twice daily.
For preventing nerve damage caused by cisplatin: vitamin E (alpha-tocopherol) 300 mg daily with each chemotherapy treatment and for up to 3 months after stopping cisplatin therapy.
For improving effectiveness of nitrates used for heart disease: vitamin E 200 mg three times daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28326458
Curator's Comment: In RAW264.7 cells, vitamin E-rich nanoemulsion significantly enhanced the secretion of Th1 cytokines and down-regulated the secretion of Th2 cytokine. In a co-culture system, vitamin E-rich nanoemulsion induced a high apoptosis rate in MDA-MB-231 cells as compared with vitamin E-low nanoemulsion.
Unknown
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 18:26:32 GMT 2025
by
admin
on
Mon Mar 31 18:26:32 GMT 2025
|
| Record UNII |
H4N855PNZ1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
335111
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
||
|
DSLD |
2421 (Number of products:1242)
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/17/1832
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
||
|
LOINC |
14590-4
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
||
|
LOINC |
74513-3
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
||
|
LIVERTOX |
30
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
||
|
LOINC |
20681-3
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
||
|
FDA ORPHAN DRUG |
678719
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
||
|
LOINC |
1823-4
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C74960
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
m11488
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | Merck Index | ||
|
D024502
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
237099
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
ALPHA-TOCOPHEROL
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
H4N855PNZ1
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
215-798-8
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
1667600
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
CHEMBL47
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
781
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
1406-18-4
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
H4N855PNZ1
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
18145
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
SUB16355MIG
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY | |||
|
100000079650
Created by
admin on Mon Mar 31 18:26:32 GMT 2025 , Edited by admin on Mon Mar 31 18:26:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SUB_CONCEPT->SUBSTANCE | |||
|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |